Crizotinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Crizotinib: From ALK-Positive Lung Cancer to Gingival Fibromatosis
One-Sentence Summary
Crizotinib is an oral kinase inhibitor targeting ALK, ROS1 and MET, and the literature in this pack describes it as approved for ALK-positive non-small cell lung cancer. The TxGNN model predicts it may be effective for gingival fibromatosis, but there are 0 clinical trials and 0 publications supporting this prediction, so it rests on the graph model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the license data. The literature describes approval for ALK-positive NSCLC. |
| Predicted New Indication | Fibromatosis, gingival |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 5 license records (2 unique NDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the source record. Literature elsewhere in the pack describes crizotinib as an ATP-competitive inhibitor of the receptor tyrosine kinases c-Met, ALK and ROS1. It is established in ALK- and ROS1-driven lung cancer.
The prediction does not have a clear mechanistic bridge. The data supplied document no link between ALK, ROS1 or MET inhibition and hereditary gingival fibromatosis, which is a benign overgrowth of gum tissue. Nothing supports the 99.81% score beyond the model itself, so it should be read as a hypothesis-generation signal. A mechanism would have to be worked out before any further investment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| NDA217581 | Xalkori (Pfizer) | Capsule, coated pellets |
| NDA202570 | Xalkori (Pfizer) | Capsule |
Both products are oral. The five license records in the source contain only these two unique NDAs, and none includes an approved-indication text.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (ALK/ROS1/MET tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Literature reports hepatotoxicity, cardiac effects (bradycardia, QT prolongation) and drug-induced lung injury, so liver function, heart rate/ECG and respiratory symptoms are relevant. CBC is also advisable. |
| Handling Protection | Please refer to the package insert and institutional hazardous-drug handling policy |
Safety Considerations
No package insert warnings, contraindications or drug-interaction data were available in the source record. Please refer to the package insert for safety information.
The pack’s literature for other predicted indications reports these crizotinib safety signals:
- A case of fatal fulminant liver failure
- Multiple cardiac toxicities in one patient (bradycardia, QT prolongation, ventricular arrhythmia, pericarditis)
- Drug-induced organizing pneumonia and lung injury
- A multisystem toxicity review covering hepatotoxicity, cardiotoxicity and interstitial lung disease
These are relevant if crizotinib were ever considered for a benign condition, where the risk-benefit balance is much tighter than in advanced cancer.
Conclusion and Next Steps
Decision: Hold
Rationale: This is a model-only prediction (L5) with no trials, no literature and no documented mechanistic link, for a benign condition in which the known toxicity profile of crizotinib weighs heavily.
To proceed, the following is needed:
- A plausible mechanistic link between ALK/ROS1/MET signaling and gingival fibromatosis, shown by preclinical or genetic evidence
- Original indication and mechanism of action data, plus package insert warnings and contraindications (currently missing)
- A benefit-risk assessment given the reported hepatic, cardiac and pulmonary toxicity
For prioritization: in the same prediction list, lung hilum carcinoma and lung germ cell tumor have some supporting evidence (L4, Research Question), though still case-report or tumor-agnostic level.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.